<?xml version='1.0' encoding='utf-8'?>
<document id="31375472"><sentence text="Development and Validation of a Higher-Throughput Cytochrome P450 Inhibition Assay with the Novel Cofactor-Supplemented Permeabilized Cryopreserved Human Hepatocytes (MetMax Human Hepatocytes)." /><sentence text="Here, we report the application of a novel hepatocyte system, the cofactor-supplemented permeabilized cryopreserved human hepatocytes [MetMax human hepatocytes (MMHHs)] in a higher-throughput 384-well plate assay for the evaluation of cytochrome P450 (P450) inhibition" /><sentence text=" The assay was created to develop physiologically relevant P450 inhibition information, taking advantage of the complete organelle composition and their associated drug-metabolizing enzymes of the MMHH but with the ease of use of human liver microsomes, including storage at -80°C instead of in liquid nitrogen, and thaw and use without centrifugation and microscopic evaluation as required for intact hepatocytes"><entity charOffset="302-310" id="DDI-PubMed.31375472.s3.e0" text="nitrogen" /></sentence><sentence text=" Nine key P450 isoforms for drug metabolism (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4) were evaluated using multiple isoform-selective inhibitors" /><sentence text=" Results with MMHH were found to be comparable to those obtained with intact cryopreserved human hepatocytes (CHHs)" /><sentence text=" Isoform-selective drug-metabolizing enzyme pathways evaluated were phenacetin O-deethylation (CYP1A2), coumarin 7-hydroxylation (CYP2A6), bupropion hydroxylation (CYP2B6), amodiaquine N-deethylation (CYP2C8), diclofenac 4-hydroxylation (CYP2C9), s-mephenytoin 4'-hydroxylation (CYP2C19), dextromethorphan O-demethylation (CYP2D6), chlorzoxazone 6-hydroxylation (CYP2E1), and midazolam 1'-hydroxylation and testosterone 6β-hydroxylation (CYP3A4)"><entity charOffset="68-78" id="DDI-PubMed.31375472.s6.e0" text="phenacetin" /><entity charOffset="139-148" id="DDI-PubMed.31375472.s6.e1" text="bupropion" /><entity charOffset="289-305" id="DDI-PubMed.31375472.s6.e2" text="dextromethorphan" /><entity charOffset="332-345" id="DDI-PubMed.31375472.s6.e3" text="chlorzoxazone" /><entity charOffset="407-419" id="DDI-PubMed.31375472.s6.e4" text="testosterone" /><pair ddi="false" e1="DDI-PubMed.31375472.s6.e0" e2="DDI-PubMed.31375472.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31375472.s6.e0" e2="DDI-PubMed.31375472.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31375472.s6.e0" e2="DDI-PubMed.31375472.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31375472.s6.e0" e2="DDI-PubMed.31375472.s6.e3" /><pair ddi="false" e1="DDI-PubMed.31375472.s6.e0" e2="DDI-PubMed.31375472.s6.e4" /><pair ddi="false" e1="DDI-PubMed.31375472.s6.e1" e2="DDI-PubMed.31375472.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31375472.s6.e1" e2="DDI-PubMed.31375472.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31375472.s6.e1" e2="DDI-PubMed.31375472.s6.e3" /><pair ddi="false" e1="DDI-PubMed.31375472.s6.e1" e2="DDI-PubMed.31375472.s6.e4" /><pair ddi="false" e1="DDI-PubMed.31375472.s6.e2" e2="DDI-PubMed.31375472.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31375472.s6.e2" e2="DDI-PubMed.31375472.s6.e3" /><pair ddi="false" e1="DDI-PubMed.31375472.s6.e2" e2="DDI-PubMed.31375472.s6.e4" /><pair ddi="false" e1="DDI-PubMed.31375472.s6.e3" e2="DDI-PubMed.31375472.s6.e3" /><pair ddi="false" e1="DDI-PubMed.31375472.s6.e3" e2="DDI-PubMed.31375472.s6.e4" /></sentence><sentence text=" The Km values obtained with MMHHs were comparable with those reported in the literature for CHHs" /><sentence text=" Using substrate concentrations at or near Km values, the IC50 values for the standard inhibitors against the P450 activities were found to be comparable between MMHHs and CHHs, with 73% and 84% of values falling within 2-fold and 3-fold, respectively, from the line of unity" /><sentence text=" The results indicate that MMHHs can be an efficient experimental system for the evaluation of P450 inhibition in hepatocytes" /><sentence text=" SIGNIFICANCE STATEMENT: MetMax human hepatocytes (MMHHs) are cofactor-supplemented cryopreserved human hepatocytes with the complete drug-metabolizing enzyme pathways of the conventional hepatocytes but with the convenience of human liver microsomes, including storage at -80°C instead of in liquid nitrogen, and direct thaw and use without a need for centrifugation and microscopic examination"><entity charOffset="300-308" id="DDI-PubMed.31375472.s10.e0" text="nitrogen" /></sentence><sentence text=" Here, we report the application of MMHH in a high-throughput assay in a 384-well plate format for the evaluation of cytochrome P450 (P450) inhibition" /><sentence text=" Our results show that data obtained with MMHH are similar to those with conventional hepatocytes, suggesting that the MMHH 384-well P450 inhibition assay can be used routinely for the evaluation of drug-drug interaction potential of new chemical entities in drug development" /><sentence text="" /></document>